CH \$740.00 885814

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM658797

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
WILMINGTON SAVINGS FUND SOCIETY, FSB		07/01/2021	Federal Savings Bank:

RECEIVING PARTY DATA

Name:	AKORN, INC.
Street Address:	1925 West Field Court, Suite 300
Internal Address:	Suite 300
City:	Lake Forest
State/Country:	ILLINOIS
Postal Code:	60045
Entity Type:	Corporation: DELAWARE
Name:	AKORN Intermediate Company LLC
Street Address:	1925 West Field Court
Internal Address:	Suite 300
City:	Lake Forest
State/Country:	ILLINOIS
Postal Code:	60045
Entity Type:	Limited Liability Company: DELAWARE
Name:	Akorn Operating Company, LLC,
Street Address:	1925 West Field Court
Internal Address:	Suite 300
City:	Lake Forest
State/Country:	ILLINOIS
Postal Code:	60045
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 29

Property Type	Number	Word Mark
Serial Number:	88581415	
Serial Number:	88070824	RESTORES EYES NATURAL BALANCE CLEANSES E
Serial Number:	88047652	THERATEARS EXTRA
Serial Number:	88072677	RESTORES + CLEANSES + NOURISHES
	•	IRADEMARK

900628329 REEL: 007349 FRAME: 0769

Property Type	Number	Word Mark
Serial Number:	90552357	HYDROLOCK
Registration Number:	1861344	DIABETIC TUSSIN
Registration Number:	5355854	FAST AND FIERCE RELIEF
Registration Number:	4556180	JEFFREY P. GILBARD, MD
Registration Number:	2541622	MAGINEX
Registration Number:	2633768	MAG-OX 400
Registration Number:	5355853	MASTER OF MAGNESIUM
Registration Number:	4613666	MULTI-BETIC
Registration Number:	4837201	OSMO-CORRECTION
Registration Number:	3272765	PHARMACEUTICAL GRADE
Registration Number:	4846473	RESTORES EYES NATURAL BALANCE
Registration Number:	3194160	SINUS BUSTER
Registration Number:	3503088	SINUS BUSTER ALL NATURAL NASAL SPRAY
Registration Number:	3140041	STERILID
Registration Number:	5943133	THERA TEARS
Registration Number:	3181614	THERATEARS STERILID
Registration Number:	2041112	THERATEARS
Registration Number:	4843058	THERAPY FOR YOUR EYES
Registration Number:	5586699	THERATEARS EXTRA
Registration Number:	2770188	THERATEARS
Registration Number:	5291486	TYPE YOU
Registration Number:	5297364	TYPE YOU DIABETIC CARE
Registration Number:	3106587	ZOSTRIX
Registration Number:	1423561	ZOSTRIX
Registration Number:	0974841	URO-MAG

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-728-8000
Email: ipdept@willkie.com
Correspondent Name: Heather Schneider
Address Line 1: 787 Seventh Avenue

Address Line 4: New York, NEW YORK 10019

ATTORNEY DOCKET NUMBER:	127865.00001
NAME OF SUBMITTER:	Heather Schneider
SIGNATURE:	/Heather Schneider/
DATE SIGNED:	07/08/2021

Total Attachments: 10

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page1.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page2.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page3.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page4.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page5.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page6.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page7.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page8.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page9.tif

source=Akron - Release of security interest in Patents Trademarks and Copyrights (TL) (Execution Version)#page10.tif

RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS AND TRADEMARKS

This RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS AND TRADEMARKS (this "Release") dated as of July 1, 2021, is made by WILMINGTON SAVINGS FUND SOCIETY, FSB on behalf of itself and in its capacity as administrative agent and collateral agent for the Secured Parties (in such capacities, the "Administrative Agent") in favor of AKORN, INC., AKORN Intermediate Company LLC, Akorn Operating Company, LLC, and each other Person that became a Grantor under the Loan Agreement or Security Agreement (collectively the "Grantors"). Capitalized terms not defined herein shall have the meaning ascribed to them, directly or by reference, in the Security Agreement (as defined below).

WHEREAS, Akorn Operating Company LLC, the other Loan Parties from time to time party thereto, the lenders from time to time party thereto, and Administrative Agent entered into a Senior Secured Term Loan Agreement, dated as of October 1, 2020 (as amended, modified, supplemented, renewed or extended from time to time, the "Loan Agreement");

WHEREAS, pursuant to the Loan Agreement the Grantors and Administrative Agent entered into Secured Term Loan Agreement, dated as of October 1, 2020 (as amended, modified, supplemented, renewed or extended from time to time, the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered a Confirmatory Grant of Security Interest in United States Trademarks, dated October 1, 2020, in favor of the Administrative Agent (the "<u>Trademark Security Agreement</u>") as well as a Confirmatory Grant of Security Interest in United States Patents, dated October 1, 2020, in favor of the Administrative Agent (the "<u>Patent Security Agreement</u>");

WHEREAS, the Trademark Security Agreement was recorded in the United States Patent and Trademark Office on October 1, 2020 at Reel/Frame 7072/0198 and 7067/0152, and the Patent Security Agreement was recorded in the United States Patent and Trademark Office on October 1, 2020 at Reel/Frame 053955/0060 and 053954/0755; and

WHEREAS, the Administrative Agent has agreed to release, discharge and terminate its security interest in and liens upon, and relinquish its rights under the Loan Documents with respect to, certain specified collateral as provided for in this Release to the extent constituting "Specified Assets" as defined in that certain Release Letter dated as of the date hereof by and between Akorn Operating Company, LLC and Administrative Agent.

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Administrative Agent hereby agrees as follows:

1. Release.

a. The Administrative Agent, without representation, warranty or recourse of any kind, hereby releases, discharges and terminates all of its security interest and liens and related rights of any kind, nature or description it or any Secured Party holds pursuant to the Security Agreement, Trademark Security Agreement or other Loan Documents

in and to the following, in each case to the extent constituting Specified Assets (the "Released Trademark Collateral"):

- i. All Trademarks set forth on Exhibit \underline{A} hereto, together with the goodwill symbolized thereby; and
- ii. all income, royalties, damages, claims, and payments then or thereafter due or payable under and with respect to such Trademarks (including without limitation damages and payments for all causes of action arising prior to or after the date thereof for infringement of such Trademarks).
- b. The Administrative Agent, without representation, warranty or recourse of any kind, hereby releases, discharges and terminates all of its security interest and liens and related rights of any kind, nature or description it or any Secured Party holds pursuant to the Security Agreement, Patent Security Agreement, or other Loan Documents in and to the following, in each case to the extent constituting Specified Assets (the "Released Patent Collateral"):
 - i. All Patents set forth on Exhibit A hereto; and
 - ii. all income, royalties, damages, claims, and payments then or thereafter due or payable under and with respect to such Patents (including without limitation damages and payments for all causes of action arising prior to or after the date thereof for infringement of such Patents).

If and to the extent that the Administrative Agent has acquired any right, title or interest in and to the Released Trademark Collateral or the Released Patent Collateral under the Security Agreement, Trademark Security Agreement, Patent Security Agreement, or other Loan Documents, the Administrative Agent, without representation, warranty or recourse of any kind, hereby transfers, conveys and assigns such right, title or interest to the Grantor. This Release is applicable only and solely with respect to the Released Trademark Collateral and the Released Patent Collateral and to no other collateral arising under the Security Agreement, the Trademark Security Agreement or the Patent Security Agreement.

- 2. Recordation. The Administrative Agent hereby authorizes the Grantor (and any successor to such Grantor, including without limitation any person or entity hereafter holding any right, title or interest in and to any Released Trademark Collateral or Released Patent Collateral) or its designee to file this Release for recordal with the United States Patent and Trademark Office and any other applicable Governmental Authorities, and the Grantor hereby authorizes and requests that the Commissioner for Trademarks and any other applicable government officer record this Release.
- 3. <u>Further Assurances</u>. The Administrative Agent shall, at the Grantor's sole cost and expense and at the Grantor's reasonable request, execute, acknowledge and deliver to the Grantors all further releases and other documents (including without limitation Uniform Commercial Code termination statements), and take all other actions reasonably requested by a Grantor to more fully and effectively effectuate the purposes of this Release.

- 4. <u>Governing Law.</u> This Release shall be governed by, and shall be construed and enforced in accordance with, the laws of the State of New York.
- 5. Expenses; Indemnity; Governing Law; Jurisdiction; Consent to Service of Process; Waiver of Jury Trial. The express terms of Sections 9.03, 9.09 and 9.10 of the Loan Agreement are hereby incorporated by reference into this Release, mutatis mutandis.

[Signature Page Follows]

IN WITNESS WHEREOF, the Administrative Agent has duly executed this Release as of the day and year first above written.

WILMINGTON SAVINGS FUND SOCIETY, FSB, on behalf of itself and as Administrative Agent

Title: Vice President

Sxhibit A

Trademarks

21 / YOY GILCOU Y ISIOH INCSCAICH, HIC.	10111	1101010	71071101	71010	TYCW COLLEGE		Č.
+	1/2/2021	1131346	10/1/2010	1131346	New Zealand	-	2
	11/16/2005	907,931	7/29/2005	731418	Mexico	STERILID	27.
05 Advanced Vision Research, Inc	8/8/2005	1376561	8/8/2005	1376561	India	STERILID	26.
06 Advanced Vision Research, Inc.	6/14/2006	4549721	7/14/2005	4549721	EU	STERILID	25.
05 Advanced Vision Research, Inc.	7/12/2005	1064550	7/12/2005	1064550	Australia	STERILID	24.
	1/19/2009	TMA732672	1/7/2008	1378171	Canada	SINUS GENIE	23.
	9/16/2008	3,503,088	3/30/2006	78850704	USA	NASAL SPRAY	
						SINUS BUSTER ALL NATURAL	22.
07 Akorn Operating Company LLC	1/2/2007	3,194,160	4/16/2006	78862364	USA	SINUS BUSTER	21.
	1/22/2009	TMA733034	1/7/2008	1378181	Canada	SINUS BUSTER	20.
15 Akorn Operating Company LLC	11/3/2015	4,846,473	6/22/2013	85967251	USA	BALANCE	19.
07 Akorn Operating Company LLC	7/31/2007	3,272,765	11/18/2003	78329276	USA	design)	5 5
Akorn Operating Company LLC	10/20/2015	4,837,201	6/22/2013	85967253	USA	+	10 1.7
	9/30/1994	4,613,666	3/4/2014	86210334	USA	1	16.
17 Akorn Operating Company LLC	12/12/2017	5,355,853	4/20/2016	87007233	USA	MASTER OF MAGNESIUM	15.
02 Akorn Operating Company LLC	10/15/2002	2,633,768	10/23/1998	75576028	USA	MAG-OX 400	14.
02 Akorn Operating Company LLC	2/19/2002	2,541,622	5/19/2000	76052135	USA	MAGINEX	13.
	6/13/2005	TMA641833	11/20/2000	1083318	Canada	MAGINEX	12.
\dashv	6/24/2014	4,556,180	9/1/2010	85121025	USA	JEFFREY P. GILBARD, MD	11.
\dashv	1/14/2011	TMA787365	8/24/2009	1449250	Canada	HEADACHE BUSTER	10.
	12/12/2017	5,355,854	4/20/2016	87007235	USA	FAST AND FIERCE RELIEF	9.
	11/1/1994	1,861,344	5/4/1993	74389373	USA	DIABETIC TUSSIN	8.
Akorn Operating Company LLC	N/A	N/A	8/16/2019	88/581,415	USA	DESIGN ONLY	7.
Akorn Operating Company LLC	A/N	N/A	3/1/2021	90/552,357	USA	HYDROLOCK	6.
Akorn Operating Company LLC			8/9/2018	88/072,677	USA	+NOURISHES and Design	
	N/A	N/A				RESTORES + CLEANSES	iv
Akorn Operating Company LLC	A/N	N/A	7/23/2018	88/047,652	USA	THERAREARS EXTRA	4.
Advanced Vision Research, Inc.	A/N	N/A	10/1/2019	1131346	New Zealand	STERILID	3.
Akorn Operating Company LLC	N/A	N/A	8/9/2018	88/070,824	USA	Design	
						AND LASHES NOURISHES EYES TO PROMOTE HEAT THY TEARS and	
						BALANCE CLEANSES EYELIDS	į
						RESTORES EYES NATURAL	٦
Akorn Operating Company LLC	N/A	N/A	8/16/2019	88/581,415	USA	DESIGN ONLY	-
T	Keg. Date	Keg. No.	App. Date	App. No.	Jurisdiction	TILE	4

N/A N/A 130439		N/A		Kuwait	THERATEARS
986 1,4	1986	1/6	73576274	USA	ZOSTRIX
6/29/2005 3,106,587	/2005	6/29	78660833	USA	ZOSTRIX
4/6/2016 5,297,364	/2016	4/6,	86966811	USA	TYPE YOU DIABETIC CARE
4/7/2016 TMA1047727	2016	4/7/	1776093	Canada	TYPE YOU DIABETIC CARE
2015 5,291,486	2015	5/15/2015	86631044	USA	TYPE YOU
2015 TMA1040395	2015	5/15/2015	1728450	Canada	TYPE YOU
2004 3,181,614	004	7/30/2004	78459728	USA	THERATEARS STERILID
2,770,1 88	2002	7/5/2002	76427523	USA	THERATEARS
2014 1197342	2014	1/21/2014	1197342	Switzerland (IR)	THERATEARS
2014 1197342	2014	1/21/2014	1197342	Singapore (IR)	THERATEARS
3/22/2001 UK00902153476	2001	3/22/	UK00902153476	UK	THERATEARS
1/24/2014 2014/01774	2014	1/24/	2014/01774	South Africa	THERATEARS
1/21/2014 1197342	2014	1/21/	1197342	Norway (IR)	THERATEARS
1997 274324	1997	3/19/1997	274324	New Zealand	THERATEARS
N/A 155229	N/A		N/A	Lebanon	THERATEARS
1/21/2014 1197342	/2014	1/21	1197342	Register	THERATEARS
				International	
8/8/2005 1376560	2005	8/8/	1376560	India	THERATEARS
2/4/2014 201476	2014	2/4/	2014000962	Guatemala	THERATEARS
2001 2153476	2001	3/22/2001	2153476	EU	THERATEARS
2002 TMA641310	2002	9/23/2002	1153395	Canada	THERATEARS
2000 TMA573256	2000	12/4/2000	1085366	Canada	THERATEARS
1997 7301 82	1997	3/18/1997	7301 82	Australia	THERATEARS
2016 5,586,699	2016	5/25/2016	87049747	USA	THERATEARS EXTRA
2014 4,843,058	2014	4/23/2014	86260607	USA	THERAPY FOR YOUR EYES
1994 2,041,112	1994	12/27/1994	74615598	USA	THERA TEARS
7/30/2004 3,181,614	2004	7/30/	78459728	USA	THERA TEARS STERLILID
6/3/2019 5,943,133	/2019	6/3,	88457133	USA	THERA TEARS
7/29/2005 902036	/2005	7/29	731417	Mexico	THERA TEARS
1/3/2003 2996155	/2003	1/3	2996155	EU	THERA TEARS
2008 TMA766079	2008	3/17/2008	1387723	Canada	THERA LID
2004 3,140,041	2004	7/30/2004	78459733	USA	STERILID
2005 UK00904549721	2005	7/14/2005	UK00904549721	UK	STERILID

Patents

20.	19.	18.	17.	16.	15.	14.	13.	12.	11.	10.	9.	×	7.	6.	5.	4.	ယ	2.	1.	#
Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser composition and methods for using the same	Cleanser composition and methods for using the same	Cleanser compositions and methods for using the same	Cleanser compositions and methods for using the same	Title
Latvia	Italy	Ireland	Iceland	Greece	Germany	France	Finland	European	Estonia	Denmark	Cyprus	Canada	Bulgaria	Austria	Australia	U.S.	U.S.	U.S.	U.S.	Jurisdiction
10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	CA2760591	10770410.8	10770410.8	2010242866	14/722,252	12/771,246	17/211,952	16/997,148	App. No.
4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	5/27/2015	4/30/2010	3/25/2021	8/19/2020	App. Date
2424374	2424374	2424374	2424374	2424374	2424374	2424374	2424374	2424374	2424374	2424374	2424374	CA2760591	2424374	2424374	2010242866	N/A	8231912	N/A	N/A	Reg. No.
1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/2/2018	1/17/2018	1/17/2018	4/30/2010	N/A	7/31/2012	N/A	N/A	Reg. Date
Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Akorn Operating Company LLC	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Registered Owner															

39.	38.	37.	36.	35.	34.	33.	32.	31.	30.	29.	28.	27.	26.	25.	24.	23.	22.	21.
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Method of treatment using a therapeutic agent for intranasal administration	Method of treatment using a therapeutic agent for intranasal administration	Cleanser Compositions And Methods For Using The Same	Cleanser compositions and methods for using the same	Cleanser compositions and methods for using the same	Cleanser compositions and methods for using the same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same	Cleanser Compositions And Methods For Using The Same
Canada	Austria	Australia	U.S.	U.S.	United Kingdom	U.S.	U.S.	U.S.	Switzerland	Sweden	Spain	Romania	Portugal	Poland	Norway	New Zealand	Netherlands	Lithuania
2650136	7755402	2007238666	14/464,177	14/082,890	10770410.8	14/528,420	13/871,133	13/539,531	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	10770410.8	596254	10770410.8	10770410.8
4/12/2007	4/12/2007	4/12/2007	8/20/2014	11/18/2013	4/30/2010	10/30/2014	4/26/2013	7/2/2012	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	4/30/2010	11/7/2011	4/30/2010	4/30/2010
2650136	2018103	2007238666	9301988	8900643	2424374	9050288	8932653	8449928	2424374	2424374	2424374	2424374	2424374	2424374	2424374	596254	2424374	2424374
7/7/2015	8/26/2015	8/22/2013	4/5/2016	12/2/2014	1/17/2018	6/9/2015	1/13/2015	5/28/2013	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	1/17/2018	10/1/2013	1/17/2018	1/17/2018
Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Akorn Operating Company LLC	Akorn Operating Company LLC	Advanced Vision Research, Inc.	Akorn Operating Company LLC	Akorn Operating Company LLC	Akorn Operating Company LLC	Advanced Vision Research, Inc.									

52.	51.	50.	49.	48.	47.	46.	45.	4.	43.	42.	41.	40.
	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear
Switzerland	Sweden	Spain	New Zealand	Liechtenstein	Italy	Greece	Germany	France	Finland	European	Estonia	Denmark
7755402	7755402	7755402	571810	7755402	7755402	7755402	7755402	7755402	7755402	7755402	7755402	7755402
4/12/2007	4/12/2007	4/12/2007	10/7/2008	4/12/2007	4/12/2007	4/12/2007	4/12/2007	4/12/2007	4/12/2007	4/12/2007	4/12/2007	4/12/2007
2018103	2018103	2018103	571810	2018103	2018103	2018103	2018103	2018103	2018103	2018103	2018103	2018103
8/26/2015	8/26/2015	8/26/2015	10/8/2012	8/26/2015	8/26/2015	8/26/2015	8/26/2015	8/26/2015	8/26/2015	8/26/2015	8/26/2015	8/26/2015
Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.	Advanced Vision Research, Inc.

 53. Methods and compositions for the treatment of infectious colonization of the eyelid, ocular surface, skin or ear 54. Methods And Compositions For The Treatment Of Infectious Colonization Of The Eyelid, Ocular Surface Skin Or For 6/14/2012 6/14/2012 6/14/2012 6/14/2013 6/14/2013 6/14/2013 8/26/2015 Advanced Vision Research, Inc. 6/14/2017 8/26/2015 <l< th=""></l<>
13/523,512 6/14/2012 8535736 9/17/2013 7755402 4/12/2007 2018103 8/26/2015
8535736 9/17/2013 2018103 8/26/2015
8535736 9/17/2013 2018103 8/26/2015
6 9/17/2013 3 8/26/2015
9/17/2013 Akorn Operating Company LLC 8/26/2015 Advanced Vision Research, Inc.
Akorn Operating Company LLC Advanced Vision Research, Inc.
i I

RECORDED: 07/08/2021